KRKA - Start of buy-back programme

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 26 / 2020

Date of issue: 2020-07-29

Short name of the issuer

KRKA

Subject

Start of buy-back programme

Official market - legal basis

Unofficial market - legal basis

Contents of the report:

On 9 July 2020 the 26th Annual General Meeting authorized the Management Board for the acquisition of treasury shares in accordance with the Article 247 of the Companies Act (ZGD-1). The company is disclosing that it will commence with the acquisition of treasury shares in accordance with this authorization under following conditions: Sole purpose of a share buy-back programme is capital decrease of an issuer. The maximum pecuniary amount allocated to the programme is EUR 356,424,889. The maximum number of shares to be acquired is 1,844,372. Duration of the programme is 36 months from the date of the General Meeting authorization. Shares will be acquired on the regulated market at the respective market price and under the terms, that will not have an influence on the prevailing market conditions. The public will be regularly informed about these acquisitions of treasury shares. In compliance with Paragraphs 3 and 4 of Article 381 of the Companies Act (ZGD-1), the company may decrease its share capital by cancelling of all existing treasury shares and treasury shares aquired under new share buy-back programme, under a simplified procedure to debit other profit reserves.

Annexes

File Description

KRKA, TOVARNA ZDRAVIL D.D.

(fullname of the issuer)

KRKA Farmaceutyczny (far)

(short name of the issuer) (sector according to clasification of the WSE in Warsow)

8501 Nove Mesto

(post code) (city)

Smarjeska 6

(street) (number)

[phone] [phone]

(phone number) (fax)

(e-mail) (web site)

nie dotyczy

(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date Name Position / Function Signature

2020-07-29 Jože Colarič President of the Management Board